Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients

被引:12
|
作者
Minami, M
Atarashi, K
Ishiyama, A
Hirata, Y
Goto, A
Omata, M
机构
[1] Univ Tokyo, Fac Med, Dept Nephrol & Endocrinol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Fac Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan
[3] Univ Tokyo, Fac Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan
关键词
pressor hyperreactivity; hypercholesterolemia; cholesterol-lowering therapy; platelet intracellular; Ca2+ concentration; nitric oxide;
D O I
10.1291/hypres.26.273
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We previously demonstrated that normotensive patients with hypercholesterolemia showed excessive blood pressure (BP) responses to stress tests. In this study, we examined the effects of cholesterol-lowering therapy on BP in order to confirm that hypercholesterolemia plays a role in the regulation of BP. Fifteen patients with hypercholesterolemia and 24 normal cholesterolemic controls performed mental arithmetic stress (AS) and hand grip (HG) tests. BP was measured during the tests. Serum lipids and lipid peroxides were measured before the AS. Platelet intracellular free calcium concentration ([Ca2+])(i) with and without low density lipoprotein (LDL) stimulation, plasma cGMP and NOx were determined immediately before AS and at the end of each test. In hypercholesterolemic patients, the tests were repeated at the end of a 12-week treatment with 10 mg/day of pravastatin, a hepatic hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. In hypercholesterolemic patients, BP responses to both tests were greater than those of the controls. Basal and LDL-stimulated platelet [Ca2+](i) were higher, and the ratio of plasma cGMP to NOx was lower. Serum total cholesterol, LDL cholesterol and lipid peroxides were significantly decreased in association with the pravastatin treatment. Systolic BP to AS and systolic BP/diastolic BP to HG were decreased (p<0.01, p<0.01/p<0.02, respectively). Platelet [Ca2+](i) with LDL stimulation was decreased (p<0.01). Plasma cGMP was increased (p<0.05), whereas NOx was decreased (p<0.05); therefore, the ratio of cGMP to NOx was increased (p<0.05). In conclusion, excessive blood pressure responses to stress tests were improved after cholesterol-lowering therapy. This finding suggests that hypercholesterolemia itself is involved in the regulation of BP.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [21] Cholesterol-lowering effect of soy protein in normocholesterolemic and hypercholesterolemic men
    Wong, WW
    Smith, EO
    Stuff, JE
    Hachey, DL
    Heird, WC
    Pownell, HJ
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (06): : 1385S - 1389S
  • [22] Cholesterol-lowering effect of platycodin D in hypercholesterolemic ICR mice
    Zhao, Hai Lin
    Cho, Kyung-Hyun
    Ha, Young Wan
    Jeong, Tae-Sook
    Lee, Woo Song
    Kim, Yeong Shik
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 537 (1-3) : 166 - 173
  • [23] ASSOCIATIONS OF CHOLESTEROL-LOWERING BY STATINS WITH ANGER AND HOSTILITY IN HYPERCHOLESTEROLEMIC MEN
    STRANDBERG, TE
    RAIKKONEN, K
    PARTINEN, M
    PIHL, S
    VANHANEN, H
    MIETTINEN, TA
    BIOLOGICAL PSYCHIATRY, 1994, 35 (08) : 575 - 577
  • [24] Sorghum extract exerts cholesterol-lowering effects through the regulation of hepatic cholesterol metabolism in hypercholesterolemic mice
    Kim, Eunyoung
    Kim, Sehee
    Park, Yongsoon
    INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 2015, 66 (03) : 308 - 313
  • [25] CHOLESTEROL-LOWERING EFFECTS OF RICE BRAN AND RICE BRAN OIL FRACTIONS IN HYPERCHOLESTEROLEMIC HAMSTERS
    KAHLON, TS
    SAUNDERS, RM
    SAYRE, RN
    CHOW, FI
    CHIU, MM
    BETSCHART, AA
    CEREAL CHEMISTRY, 1992, 69 (05) : 485 - 489
  • [26] Appropriate use of cholesterol-lowering therapy
    Falk, Erling
    ATHEROSCLEROSIS, 2017, 262 : 198 - 199
  • [27] Need to individualise cholesterol-lowering therapy
    Luetjohann, Dieter
    Weingaertner, Oliver
    HEART, 2019, 105 (16)
  • [28] The future direction of cholesterol-lowering therapy
    Evans, M
    Roberts, A
    Rees, A
    CURRENT OPINION IN LIPIDOLOGY, 2002, 13 (06) : 663 - 669
  • [29] Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy
    Schmitz, Gerd
    Schmitz-Madry, Anna
    Ugocsai, Peter
    CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (02) : 164 - 173
  • [30] Cholesterol-lowering therapy: Is there really a controversy?
    Jungnickel, PW
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (05) : 539 - 542